“Hashtag Biotech” is a new weekly column in which OneMedPlace explores the power of Twitter and other social media tools in facilitating emerging growth company development. This week, we identify the most intriguing biotech investors using Twitter.
Frank Reynolds, of InVivo Therapeutics (NVIV), says the company is on the verge of unprecedented technology for the treatment of the spinal cord.
OneMedPlace held a 2nd reception to promote OneMedForum New York 2012 last Thursday at The Chasson Group offices.
India is emerging as a significant player in the life science sector. The 2005 patent amendments have brought India into the modern world in terms of intellectual property.
Ceplene is administered for maintenance of first remission in patients with AML, the most common type of Leukemia in adults.
S.E.A. Medical Systems, Inc. is developing solutions for making intravenous (IV) drug delivery safer for patients.
Results of a published prospective three-year clinical study have demonstrated that the Reducer is safe and effective at providing relief of angina symptoms in refractory angina patients.
IntelGenx is at the forefront of the industry with CPI-300 being the only single dose 450 mg formulation of Bupropion HCl approved by the FDA.
Hepregen is focused on improving and commercializing its microliver platform, HepatoPac, into the drug-development pipeline of pharmaceutical and biotechnology companies.
Panels consisting of leading strategic and financial investors will be followed by short presentations by promising companies. Over 100 companies will present.
Copyright © 2025 | WordPress Theme by MH Themes